Biogen and AbbVie have announced the voluntary worldwide withdrawal of marketing authorisations for daclizumab (Zinbryta) for the treatment of relapsing multiple sclerosis (MS) as a result of the “complex and evolving benefit/risk profile” of the drug.1 Following seven reported cases of inflammatory brain disorders (encephalitis and meningoencephalitis) associated with daclizumab, the European Medicines Agency (EMA) has undertaken an urgent review of the safety of the drug.2

Clinicians will be contacted directly with further information about the withdrawal of …